Molecular genetics of acute lymphoblastic leukemia

Annual Review of Pathology: Mechanisms of Disease

Volumn 4, Issue , 2009, Pages 175-198

  Teitell, Michael A ^a   Pandolfi, Pier Paolo ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Copy number variation; Mouse modeling; Oncogene addiction; Targeted therapy; Translocation

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; ABELSON KINASE; BCR ABL PROTEIN; CLATHRIN; DASATINIB; F BOX PROTEIN; FUSION PROTEIN CALM AF10; GAMMA SECRETASE INHIBITOR; HYBRID PROTEIN; IMATINIB; MIXED LINEAGE LEUKEMIA PROTEIN; NILOTINIB; NOTCH1 RECEPTOR; PROTEIN MYB; PROTEIN SERINE KINASE; PROTEIN SERINE KINASE LMO1; PROTEIN SERINE KINASE LMO2; TETRACYCLINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR HLF; TRANSCRIPTION FACTOR LYL1; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR TAL1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LEUKEMIA; B LYMPHOCYTE; BONE MARROW; CANCER CLASSIFICATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; DIMERIZATION; DISEASE COURSE; DRUG MECHANISM; FLOW CYTOMETRY; GENE DUPLICATION; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC ANALYSIS; GENETIC LINKAGE; GENOME; HOMEOBOX; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; MUTAGENESIS; MUTATION; NONHUMAN; ONCOGENE; PATHOGENESIS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPECIES DIFFERENTIATION; T CELL ACUTE LYMPHOBLASTIC LEUKEMIA; T CELL LEUKEMIA; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR GROWTH; ANIMAL; CELL LINEAGE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; MOUSE; PATHOLOGY; PHENOTYPE;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, LEUKEMIC; GENOTYPE; HUMANS; MICE; PHENOTYPE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIGNAL TRANSDUCTION;

EID: 66149113692     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev.pathol.4.110807.092227     Document Type: Review

References (153)

1. Am. Cancer Soc. 2008. Cancer facts and figures 2008. http://www.cancer. org/downloads/STT/ 2008CAFFfinalsecured.pdf. Last accessed July 7, 2008
2. Pui CH, Evans WE. 2006. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354:166-178
3. Vitale A, Guarini A, Chiaretti S, Foa R. 2006. The changing scene of adult acute lymphoblastic leukemia. Curr. Opin. Oncol. 18:652-659 (Pubitemid 44427643)
4. Greaves M. 2006. Infection, immune responses and the aetiology of childhood leukaemia. Nat. Rev. Cancer 6:193-203 (Pubitemid 43292563)
5. Greaves MF, Wiemels J. 2003. Origins of chromosome translocations in childhood leukaemia. Nat. Rev. Cancer 3:639-649 (Pubitemid 37328819)
6. Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, et al. 2008. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 319:336-339
7. Maia AT, Van Der Velden VH, Harrison CJ, Szczepanski T, Williams MD, et al. 2003. Prenatal origin of hyperdiploid acute lymphoblastic leukemia in identical twins. Leukemia 17:2202-2206 (Pubitemid 37428387)
8. Wiemels JL, Cazzaniga G, Daniotti M, Eden OB, Addison GM, et al. 1999. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 354:1499-1503 (Pubitemid 29502102)
9. Buffler PA, Kwan ML, Reynolds P, Urayama KY. 2005. Environmental and genetic risk factors for childhood leukemia: appraising the evidence. Cancer Invest. 23:60-75 (Pubitemid 40344201)
10. Kinlen L. 2004. Infections and immune factors in cancer: the role of epidemiology. Oncogene 23:6341-6348 (Pubitemid 39265503)
11. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, et al. 2002. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1:75-87 (Pubitemid 41039178)
12. Wang JC, Dick JE. 2005. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15:494-501 (Pubitemid 41253469)
13. Barabe F, Kennedy JA, Hope KJ, Dick JE. 2007. Modeling the initiation and progression of human acute leukemia in mice. Science 316:600-604 (Pubitemid 46683146)
14. Roman-Gomez J, Cordeu L, Agirre X, Jimenez-Velasco A, San Jose-Eneriz E, et al. 2007. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 109:3462-3469 (Pubitemid 46572536)
15. Omura-Minamisawa M, Diccianni MB, Batova A, Chang RC, Bridgeman LJ, et al. 2000. Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T cell acute lymphoblastic leukemia. Clin. Cancer Res. 6:1219-1228 (Pubitemid 30226201)
16. Roman-Gomez J, Castillejo JA, Jimenez A, Gonzalez MG, Moreno F, et al. 2002. 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 99:2291-2296 (Pubitemid 34525411)
17. Mi S, Lu J, Sun M, Li Z, Zhang H, et al. 2007. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc. Natl. Acad. Sci. USA 104:19971-19976
18. Brunning RD, Flandrin G, Borowitz M, Swerdlow SH, Matutes E, et al. 2001. WHO histological classification of precursor B cell and T cell neoplasms. In Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, ed. ES Jaffe, NL Harris, H Stein, JW Vardiman, pp. 110-117 Lyon: IARC
19. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. 1982. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl. Acad. Sci. USA 79:7824-7827 (Pubitemid 13182471)
20. Teitell MA, Mikkola HK. 2006. Transcriptional activators, repressors, and epigenetic modifiers controlling hematopoietic stem cell development. Pediatr. Res. 59:33-39R
21. Morse HC 3rd, Anver MR, Fredrickson TN, Haines DC, Harris AW, et al. 2002. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 100:246-258
22. Gleissner B, Gokbuget N, Bartram CR, Janssen B, Rieder H, et al. 2002. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99:1536-1543 (Pubitemid 34533023)
23. Ribeiro RC, Abromowitch M, Raimondi SC, Murphy SB, Behm F, Williams DL. 1987. Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood 70:948-953 (Pubitemid 18022366)
24. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. 1985. Structural organization of the bcr gene and its role in the Ph translocation. Nature 315:758-761 (Pubitemid 15022931)
25. Chan LC, Karhi KK, Rayter SI, Heisterkamp N, Eridani S, et al. 1987. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 325:635-637 (Pubitemid 17055688)
26. Konopka JB, Watanabe SM, Witte ON. 1984. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:1035-1042
27. Harrison SC. 2003. Variation on an Src-like theme. Cell 112:737-740
28. Tanis KQ, Veach D, Duewel HS, Bornmann WG, Koleske AJ. 2003. Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Mol. Cell Biol. 23:3884-3896 (Pubitemid 36597467)
29. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, et al. 1994. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 13:764-773 (Pubitemid 24057507)
30. Tauchi T, Boswell HS, Leibowitz D, Broxmeyer HE. 1994. Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway. J. Exp. Med. 179:167-175 (Pubitemid 24012981)
31. Kharas MG, Fruman DA. 2005. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res. 65:2047-2053 (Pubitemid 40490106)
32. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:1031-1037 (Pubitemid 32267972)
33. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:561-566 (Pubitemid 26151518)
34. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, et al. 2001. Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. 21:499-512 (Pubitemid 32959239)
35. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, et al. 2002. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62:4236-4243 (Pubitemid 34827278)
36. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. 2000. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938-1942 (Pubitemid 30704121)
37. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880 (Pubitemid 32743979)
38. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125 (Pubitemid 41039112)
39. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. 2004. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401 (Pubitemid 38938156)
40. Armstrong SA, Look AT. 2005. Molecular genetics of acute lymphoblastic leukemia. J. Clin. Oncol. 23:6306-6315 (Pubitemid 46218840)
41. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, et al. 2001. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344:1038-1042 (Pubitemid 32267973)
42. Heerema NA, Harbott J, Galimberti S, Camitta BM, Gaynon PS, et al. 2004. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia 18:693-702 (Pubitemid 38500187)
43. Primo D, Tabernero MD, Perez JJ, Rasillo A, Sayagues JM, et al. 2005. Genetic heterogeneity of BCR/ABL+ adult B cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. Leukemia 19:713-720 (Pubitemid 40663089)
44. Sherr CJ, McCormick F. 2002. The RB and p53 pathways in cancer. Cancer Cell 2:103-112
45. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27-37 (Pubitemid 26116804)
46. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, et al. 2008. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453:110-114 (Pubitemid 351630327)
47. Ng SY, Yoshida T, Georgopoulos K. 2007. Ikaros and chromatin regulation in early hematopoiesis. Curr. Opin. Immunol. 19:116-122 (Pubitemid 46356975)
48. Kirstetter P, Thomas M, Dierich A, Kastner P, Chan S. 2002. Ikaros is critical for B cell differentiation and function. Eur. J. Immunol. 32:720-730 (Pubitemid 34257550)
49. Wong S, Witte ON. 2004. The BCR-ABL story: bench to bedside and back. Annu. Rev. Immunol. 22:247-306 (Pubitemid 38680424)
50. Williams RT, Roussel MF, Sherr CJ. 2006. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 103:6688-6693
51. Wong S, Witte ON. 2001. Modeling Philadelphia chromosome positive leukemias. Oncogene 20:5644-5659 (Pubitemid 32928104)
52. Krivtsov AV, Armstrong SA. 2007. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 7:823-833
53. Meyer C, Schneider B, Jakob S, Strehl S, Attarbaschi A, et al. 2006. The MLL recombinome of acute leukemias. Leukemia 20:777-784
54. Ernst P, Fisher JK, Avery W, Wade S, Foy D, Korsmeyer SJ. 2004. Definitive hematopoiesis requires the mixed-lineage leukemia gene. Dev. Cell 6:437-443 (Pubitemid 38364574)
55. Ernst P, Mabon M, Davidson AJ, Zon LI, Korsmeyer SJ. 2004. An Mll-dependent Hox program drives hematopoietic progenitor expansion. Curr. Biol. 14:2063-2069 (Pubitemid 39547963)
56. Attarbaschi A, Mann G, Strehl S, Konig M, Steiner M, et al. 2007. Deletion of 11q23 is a highly specific nonrandom secondary genetic abnormality of ETV6/RUNX1-rearranged childhood acute lymphoblastic leukemia. Leukemia 21:584-586 (Pubitemid 46306581)
57. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, et al. 1995. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 92:4917-4921
58. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. 1996. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-330 (Pubitemid 26042836)
59. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. 1996. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl. Acad. Sci. USA 93:3444-3449 (Pubitemid 26125639)
60. Hock H, Meade E, Medeiros S, Schindler JW, Valk PJ, et al. 2004. Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. Genes Dev. 18:2336-2341 (Pubitemid 39304679)
61. Fears S, Gavin M, Zhang DE, Hetherington C, Ben-David Y, et al. 1997. Functional characterization of ETV6 and ETV6/CBFA2 in the regulation of the MCSFR proximal promoter. Proc. Natl. Acad. Sci. USA 94:1949-1954 (Pubitemid 27113942)
62. Hiebert SW, Sun W, Davis JN, Golub T, Shurtleff S, et al. 1996. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol. Cell Biol. 16:1349-1355 (Pubitemid 26095605)
63. Rompaey LV, Potter M, Adams C, Grosveld G. 2000. Tel induces aG1 arrest and suppresses Ras-induced transformation. Oncogene 19:5244-5250
64. Bernardin F, Yang Y, Cleaves R, Zahurak M, Cheng L, et al. 2002. TEL-AML1, expressed from t(12;21) in human acute lymphocytic leukemia, induces acute leukemia in mice. Cancer Res. 62:3904-3908 (Pubitemid 34791049)
65. Quong MW, Romanow WJ, Murre C. 2002. E protein function in lymphocyte development. Annu. Rev. Immunol. 20:301-322
66. Nutt SL, Heavey B, Rolink AG, Busslinger M. 1999. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 401:556-562 (Pubitemid 129517063)
67. Rolink AG, Schaniel C, Busslinger M, Nutt SL, Melchers F. 2000. Fidelity and infidelity in commitment to B-lymphocyte lineage development. Immunol. Rev. 175:104-111 (Pubitemid 30427160)
68. Urbanek P, Wang ZQ, Fetka I, Wagner EF, Busslinger M. 1994. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. Cell 79:901-912 (Pubitemid 24371980)
69. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, et al. 2007. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446:758-764 (Pubitemid 46582031)
70. Bousquet M, Broccardo C, Quelen C, Meggetto F, Kuhlein E, et al. 2007. A novel PAX5-ELN fusion protein identified in B cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood 109:3417-3423 (Pubitemid 46572531)
71. Cortes M, Wong E, Koipally J, Georgopoulos K. 1999. Control of lymphocyte development by the Ikaros gene family. Curr. Opin. Immunol. 11:167-171 (Pubitemid 29154901)
72. Georgopoulos K. 2002. Haematopoietic cell-fate decisions, chromatin regulation and ikaros. Nat. Rev. Immunol. 2:162-174 (Pubitemid 37328763)
73. Wang JH, Avitahl N, Cariappa A, Friedrich C, Ikeda T, et al. 1998. Aiolos regulates B cell activation and maturation to effector state. Immunity 9:543-553 (Pubitemid 28499205)
74. Schmitt C, Tonnelle C, Dalloul A, Chabannon C, Debre P, Rebollo A. 2002. Aiolos and Ikaros: regulators of lymphocyte development, homeostasis and lymphoproliferation. Apoptosis 7:277-284 (Pubitemid 34633468)
75. O'Neil J, Look AT. 2007. Mechanisms of transcription factor deregulation in lymphoid cell transformation. Oncogene 26:6838-6849 (Pubitemid 47585107)
76. Kamps MP, Murre C, Sun XH, Baltimore D. 1990. A new homeobox gene contributes theDNAbinding domain of the t(1;19) translocation protein in pre-B-ALL. Cell 60:547-555 (Pubitemid 20083811)
77. Aspland SE, Bendall HH, Murre C. 2001. The role of E2A-PBX1 in leukemogenesis. Oncogene 20:5708-5717
78. Hunger SP, Ohyashiki K, Toyama K, Cleary ML. 1992. Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. Genes Dev. 6:1608-1620
79. Inaba T, Roberts WM, Shapiro LH, Jolly KW, Raimondi SC, et al. 1992. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science 257:531-534
80. Seidel MG, Look AT. 2001. E2A-HLF usurps control of evolutionarily conserved survival pathways. Oncogene 20:5718-5725
81. Hunger SP. 1996. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 87:1211-1224
82. Yoshihara T, Inaba T, Shapiro LH, Kato JY, Look AT. 1995. E2A-HLF-mediated cell transformation requires both the transactivation domains of E2A and the leucine zipper dimerization domain of HLF. Mol. Cell Biol. 15:3247-3255
83. Inoue A, Seidel MG, Wu W, Kamizono S, Ferrando AA, et al. 2002. Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. Cancer Cell 2:279-288 (Pubitemid 41043962)
84. Aster JA, Pear WS, Blacklow SC. 2008. Notch signaling in leukemia. Annu. Rev. Pathol. Mech. Dis. 3:587-613
85. Bray SJ. 2006. Notch signalling: a simple pathway becomes complex. Nat. Rev. Mol. Cell Biol. 7:678-689
86. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, et al. 1991. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66:649-661 (Pubitemid 121001701)
87. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, et al. 2004. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306:269-271 (Pubitemid 39336870)
88. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, et al. 2006. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl. Acad. Sci. USA 103:18261-18266 (Pubitemid 44871646)
89. Ciofani M, Zuniga-Pflucker JC. 2005. Notch promotes survival of pre-T cells at the β-selection checkpoint by regulating cellular metabolism. Nat. Immunol. 6:881-888 (Pubitemid 43090442)
90. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, et al. 2007. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T cell leukemia. Nat. Med. 13:1203-1210 (Pubitemid 47530629)
91. Gutierrez A, Look AT. 2007. NOTCH and PI3K-AKT pathways intertwined. Cancer Cell 12:411-413
92. Robey E, Chang D, Itano A, Cado D, Alexander H, et al. 1996. An activated form of Notch influences the choice between CD4 and CD8 T cell lineages. Cell 87:483-492 (Pubitemid 26374322)
93. Beverly LJ, Capobianco AJ. 2003. Perturbation of Ikaros isoform selection by MLV integration is a cooperative event in Notch(IC)-induced T cell leukemogenesis. Cancer Cell 3:551-564
94. Winandy S, Wu P, Georgopoulos K. 1995. A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. Cell 83:289-299
95. Aster JC, Xu L, Karnell FG, Patriub V, Pui JC, Pear WS. 2000. Essential roles for ankyrin repeat and transactivation domains in induction of T cell leukemia by notch1. Mol. Cell Biol. 20:7505-7515 (Pubitemid 30736875)
96. Girard L, Hanna Z, Beaulieu N, Hoemann CD, Simard C, et al. 1996. Frequent provirus insertional mutagenesis of Notch1 in thymomas of MMTVD/myc transgenic mice suggests a collaboration of c-myc and Notch1 for oncogenesis. Genes Dev. 10:1930-1944 (Pubitemid 26281687)
97. Hoemann CD, Beaulieu N, Girard L, Rebai N, Jolicoeur P. 2000. Two distinct Notch1 mutant alleles are involved in the induction of T cell leukemia in c-myc transgenic mice. Mol. Cell Biol. 20:3831-3842 (Pubitemid 30314482)
98. Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B, et al. 1996. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J. Exp. Med. 183:2283-2291 (Pubitemid 26158919)
99. Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, et al. 1998. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor-suppressor gene in mice. Curr. Biol. 8:1169-1178 (Pubitemid 28494715)
100. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. 1998. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19:348-55
101. Welcker M, Clurman BE. 2008. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 8:83-93 (Pubitemid 351161321)
102. Wu G, Lyapina S, Das I, Li J, Gurney M, et al. 2001. SEL-10 is an inhibitor of notch signaling that targets notch for ubiquitin-mediated protein degradation. Mol. Cell Biol. 21:7403-7415 (Pubitemid 32953491)
103. Malyukova A, Dohda T, von der Lehr N, Akhondi S, Corcoran M, et al. 2007. The tumor suppressor gene hCDC4 is frequently mutated in human T cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res. 67:5611-5616 (Pubitemid 46984990)
104. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, et al. 2007. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447:966-971 (Pubitemid 46975753)
105. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, et al. 2007. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors. J. Exp. Med. 204:1813-1824 (Pubitemid 47236319)
106. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, et al. 2007. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J. Exp. Med. 204:1825-1835 (Pubitemid 47236320)
107. Onoyama I, Tsunematsu R, Matsumoto A, Kimura T, de Alboran IM, et al. 2007. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J. Exp. Med. 204:2875-2888 (Pubitemid 350179557)
108. Soulier J, Clappier E, Cayuela JM, Regnault A, Garcia-Peydro M, et al. 2005. HOXA genes are included in genetic and biologic networks defining human acute T cell leukemia (T-ALL). Blood 106:274-286 (Pubitemid 40967203)
109. Speleman F, Cauwelier B, Dastugue N, Cools J, Verhasselt B, et al. 2005. A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T cell acute lymphoblastic leukemias. Leukemia 19:358-366 (Pubitemid 40403311)
110. Dear TN, Colledge WH, Carlton MB, Lavenir I, Larson T, et al. 1995. The Hox11 gene is essential for cell survival during spleen development. Development 121:2909-2915
111. Roberts CW, Shutter JR, Korsmeyer SJ. 1994. Hox11 controls the genesis of the spleen. Nature 368:747-749
112. Hatano M, Roberts CW, Minden M, Crist WM, Korsmeyer SJ. 1991. Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia. Science 253:79-82 (Pubitemid 21917124)
113. Owens BM, Hawley TS, Spain LM, Kerkel KA, Hawley RG. 2006. TLX1/HOX11-mediated disruption of primary thymocyte differentiation prior to the CD4+CD8+ double-positive stage. Br. J. Haematol. 132:216-229
114. Riz I, Hawley RG. 2005. G1/S transcriptional networks modulated by the HOX11/TLX1 oncogene of T cell acute lymphoblastic leukemia. Oncogene 24:5561-5575 (Pubitemid 43119351)
115. Hough MR, Reis MD, Singaraja R, Bryce DM, Kamel-Reid S, et al. 1998. A model for spontaneous B-lineage lymphomas in IgHmu-HOX11 transgenic mice. Proc. Natl. Acad. Sci. USA 95:13853-13858 (Pubitemid 28523062)
116. Su XY, Della-Valle V, Andre-Schmutz I, Lemercier C, Radford-Weiss I, et al. 2006. HOX11L2/TLX3 is transcriptionally activated through T cell regulatory elements downstream of BCL11B as a result of the t(5;14)(q35;q32). Blood 108:4198-4201 (Pubitemid 44913293)
117. Mikkola HK, Klintman J, Yang H, Hock H, Schlaeger TM, et al. 2003. Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. Nature 421:547-551 (Pubitemid 36168449)
118. Aplan PD, Jones CA, Chervinsky DS, Zhao X, Ellsworth M, et al. 1997. An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T cell malignancies in transgenic mice. EMBO J. 16:2408-2419 (Pubitemid 27258639)
119. Aplan PD, Lombardi DP, Reaman GH, Sather HN, Hammond GD, Kirsch IR. 1992. Involvement of the putative hematopoietic transcription factor SCL in T cell acute lymphoblastic leukemia. Blood 79:1327-1333
120. Xia Y, Brown L, Yang CY, Tsan JT, Siciliano MJ, et al. 1991. TAL2, a helix-loop-helix gene activated by the (7;9)(q34;q32) translocation in human T cell leukemia. Proc. Natl. Acad. Sci. USA 88:11416-11420 (Pubitemid 21916052)
121. Bain G, Engel I, Robanus Maandag EC, te Riele HP, Voland JR, et al. 1997. E2A deficiency leads to abnormalities in αβ T cell development and to rapid development of T cell lymphomas. Mol. Cell Biol. 17:4782-4791
122. O'Neil J, Billa M, Oikemus S, Kelliher M. 2001. The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice. Oncogene 20:3897-3905 (Pubitemid 32646200)
123. O'Neil J, Shank J, Cusson N, Murre C, Kelliher M. 2004. TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 5:587-596 (Pubitemid 38748920)
124. Curtis DJ, Robb L, Strasser A, Begley CG. 1997. The CD2-scl transgene alters the phenotype and frequency of T-lymphomas in N-ras transgenic or p53 deficient mice. Oncogene 15:2975-2983 (Pubitemid 28008990)
125. Condorelli GL, Facchiano F, Valtieri M, Proietti E, Vitelli L, et al. 1996. T cell-directed TAL-1 expression induces T cell malignancies in transgenic mice. Cancer Res. 56:5113-5119 (Pubitemid 26383021)
126. Hsu HL, Wadman I, Baer R. 1994. Formation of in vivo complexes between theTAL1 and E2A polypeptides of leukemic T cells. Proc. Natl. Acad. Sci. USA 91:3181-3185 (Pubitemid 24130199)
127. Ferrando AA, Look AT. 2003. Gene expression profiling in T cell acute lymphoblastic leukemia. Semin. Hematol. 40:274-280 (Pubitemid 37296777)
128. Mellentin JD, Smith SD, Cleary ML. 1989. lyl-1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif. Cell 58:77-83
129. Zhong Y, Jiang L, Hiai H, Toyokuni S, Yamada Y. 2007. Overexpression of a transcription factor LYL1 induces T- and B-cell lymphoma in mice. Oncogene 26:6937-6947 (Pubitemid 47609075)
130. Mucenski ML, McLain K, Kier AB, Swerdlow SH, Schreiner CM, et al. 1991. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell 65:677-689
131. Pearson R, Weston K. 2000. c-Myb regulates the proliferation of immature thymocytes following â- selection. EMBO J. 19:6112-6120 (Pubitemid 30943336)
132. Clappier E, Cuccuini W, Kalota A, Crinquette A, Cayuela JM, et al. 2007. The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood 110:1251-1261 (Pubitemid 47281423)
133. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, et al. 2007. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat. Genet. 39:593-595 (Pubitemid 46676109)
134. O'Neil J, Tchinda J, Gutierrez A, Moreau L, Maser RS, et al. 2007. Alu elements mediate MYB gene tandem duplication in human T-ALL. J. Exp. Med. 204:3059-3066
135. Valge-Archer VE, Osada H, Warren AJ, Forster A, Li J, et al. 1994. The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells. Proc. Natl. Acad. Sci. USA 91:8617-8621 (Pubitemid 24273715)
136. McGuire EA, Rintoul CE, Sclar GM, Korsmeyer SJ. 1992. Thymic overexpression of Ttg-1 in transgenic mice results in T cell acute lymphoblastic leukemia/lymphoma. Mol. Cell Biol. 12:4186-4196
137. Van Vlierberghe P, van Grotel M, Beverloo HB, Lee C, Helgason T, et al. 2006. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T cell acute lymphoblastic leukemia. Blood 108:3520-3529 (Pubitemid 44776895)
138. Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH. 1998. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc. Natl. Acad. Sci. USA 95:3890-3895 (Pubitemid 28173224)
139. Neale GA, Rehg JE, Goorha RM. 1995. Ectopic expression of rhombotin-2 causes selective expansion of CD4-CD8 lymphocytes in the thymus and T cell tumors in transgenic mice. Blood 86:3060-3071
140. Larson RC, Fisch P, LarsonTA, Lavenir I, Langford T, et al. 1994. T cell tumours of disparate phenotype in mice transgenic for Rbtn-2. Oncogene 9:3675-3681 (Pubitemid 24359406)
141. Larson RC, Lavenir I, Larson TA, Baer R, Warren AJ, et al. 1996. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J. 15:1021-1027 (Pubitemid 26077830)
142. de Wind N, Dekker M, Berns A, Radman M, te Riele H. 1995. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 82:321-330
143. Lowsky R, DeCoteau JF, Reitmair AH, Ichinohasama R, Dong WF, et al. 1997. Defects of the mismatch repair gene MSH2 are implicated in the development of murine and human lymphoblastic lymphomas and are associated with the aberrant expression of rhombotin-2 (Lmo-2) andTal-1 (SCL). Blood 89:2276-2282 (Pubitemid 27143272)
144. Whiteside D, McLeod R, Graham G, Steckley JL, Booth K, et al. 2002. A homozygous germ-line mutation in the human MSH2 gene predisposes to hematological malignancy and multiple café-au-lait spots. Cancer Res. 62:359-362 (Pubitemid 34106403)
145. Dreyling MH, Martinez-Climent JA, Zheng M, Mao J, Rowley JD, Bohlander SK. 1996. The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family. Proc. Natl. Acad. Sci. USA 93:4804-4809 (Pubitemid 26162832)
146. Archangelo LF, Glasner J, Krause A, Bohlander SK. 2006. The novelCALMinteractor CATS influences the subcellular localization of the leukemogenic fusion protein CALM/AF10. Oncogene 25:4099-4109 (Pubitemid 44024872)
147. Chaplin T, Bernard O, Beverloo HB, Saha V, Hagemeijer A, et al. 1995. The t(10;11) translocation in acute myeloid leukemia (M5) consistently fuses the leucine zipper motif of AF10 onto the HRX gene. Blood 86:2073-2076
148. Dik WA, Brahim W, Braun C, Asnafi V, Dastugue N, et al. 2005. CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes. Leukemia 19:1948-1957 (Pubitemid 41554004)
149. Cayuela JM, Madani A, Sanhes L, Stern MH, Sigaux F. 1996. Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T cell acute lymphoblastic leukemia. Blood 87:2180-2186 (Pubitemid 26086856)
150. Deshpande AJ, Cusan M, Rawat VP, Reuter H, Krause A, et al. 2006. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell 10:363-374 (Pubitemid 44693467)
151. Caudell D, Zhang Z, Chung YJ, Aplan PD. 2007. Expression of a CALM-AF10 fusion gene leads to Hoxa cluster overexpression and acute leukemia in transgenic mice. Cancer Res. 67:8022-8031 (Pubitemid 47395136)
152. Mikkola HK, Orkin SH. 2006. The journey of developing hematopoietic stem cells. Development 133:3733-3744 (Pubitemid 44650952)
153. Vivanco I, Sawyers CL. 2002. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2:489-501 (Pubitemid 37328931)